Cellectis is a biotech company focused on developing immunotherapies based on gene edited engineered CAR-T cells (UCART).

Cellectis – gene-editing

The field of adoptive immunotherapy is evolving quickly, with T cells armed with a Chimeric Antigen Receptor (CAR) being used to fight cancerous cells. CARs are constructed by assembling domains from different proteins, including an extracellular domain containing a region that recognizes the targeted antigen and a spacer region that links it to the transmembrane domain. The target-binding moiety is usually derived from an antibody. Then an intracellular domain is responsible for transmitting an activation signal to the cell upon antigen recognition, causing the CAR-engineered cell to attack the tumor cell. Genome engineering is at the heart of this revolution, and this new technology relies mainly on the use of engineered nucleases modifying the genome of T cells to give them new properties. Cellectis is specialized in genome engineering based on its flagship TALEN products, meganucleases and electroporation PulseAgile technology. Allogeneic T cells engineered by Cellectis may be used to overcome the limitations of autologous (patient-derived) adoptive immunotherapies, eventually making it possible to treat many cancer patients using a standardized, off-the-shelf therapeutic product. Thus, Cellectis is developing innovative cancer products based on engineered T cells armed with a CAR to target liquid and solid tumors. Cellectis is focusing on certain types of cancers, particularly leukemia (B cells malignancies, Acute lymphoblastic leukemia (ALL), Chronic lymphocytic leukemia (CLL), Acute myeloid leukemia (AML), Multiple myeloma, etc…) and solid tumors (12 antigenic targets against pancreatic cancer, non-small-cell lung cancer, glioblastoma, etc…).

Cellectis was founded in 1999. Executive Committee is composed by André Choulika, Mathieu Simon, David Sourdive, Philippe Duchateau and Thierry Moulin. Board of Directors is composed by André Choulika, David Sourdive, Alain Godard, Pierre Bastid, Laurent Arthaud, Annick Schwebig and Mathieu Simon. Cellectis is listed on the NYSE Alternext market (ALCLS). Using its pioneering genome-engineering technologies, Cellectis’ goal is to create innovative products in multiple fields and with various target markets.

More about Cellectis : www.cellectis.com

Cellectis – immunotherapies – gene edited engineered CAR-T cells – UCART – gene-editing – Chimeric Antigen Receptor – CAR – genome engineering – engineered nucleases – ALCLS

Cellectis – immunotherapy – gene edited engineered CAR-T cell – UCART – gene edited engineered T cell – adoptive immunotherapy – adoptive immunotherapies – Chimeric Antigen Receptor – T-cell – T-cells – CAR-engineered cell – CAR engineered cell – gene engineering – engineered nuclease – TALEN products – meganucleases – electroporation PulseAgile technology – PulseAgile – TALEN – meganuclease – allogeneic T cells engineered – allogeneic T-cells engineered – autologous adoptive immunotherapies – autologous adoptive immunotherapy – leukemia – B cells malignancies – Acute lymphoblastic leukemia – ALL – Chronic lymphocytic leukemia – CLL – Acute myeloid leukemia – AML -Multiple myeloma – pancreatic cancer – non-small-cell lung cancer – glioblastoma – André Choulika – Mathieu Simon – David Sourdive – Philippe Duchateau – Thierry Moulin – Andre Choulika – David Sourdive – Alain Godard – Pierre Bastid – Laurent Arthaud – Annick Schwebig – Mathieu Simon – ALCLS